A tale of two insulins : Understanding basal insulin therapy in type 2 diabetes

Thesis

Cover

Titlepage

Contents

Chapter 1 Introduction

Chapter 2 Insulin therapy for type 2 diabetes

Chapter 3 The interpretation of glucose clamp studies of long- acting insulin analogues: from physiology to marketing and back

Chapter 4 Higher dose requirements with insulin detemir in type 2 diabetes - three cases and a review of the literature

Chapter 5 Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia

Chapter 6 Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes

Chapter 7 Rationale, design and baseline data of the insulin glargine (Lantus) vs. insulin detemir (Levemir) Treat-To-Target (L2T3) study: a multinational, randomised non-inferiority trial of basal insulin initiation in type 2 diabetes

Chapter 8 A 24-week, randomised, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs

Chapter 9 Continuation vs. discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes

Chapter 10 Summary and recommendations

Chapter 11 Samenvatting en aanbevelingen

Dankwoord